Progress of drug therapy for children with ulcerative colitis
10.3760/cma.j.issn.1673-4408.2023.09.003
- VernacularTitle:儿童溃疡性结肠炎药物治疗研究进展
- Author:
Dexiu GUAN
1
;
Yongmei ZHANG
;
Jie WU
Author Information
1. 国家儿童医学中心 首都医科大学附属北京儿童医院消化科 100045
- Keywords:
Children;
Ulcerative colitis;
Drug therapy
- From:
International Journal of Pediatrics
2023;50(9):584-589
- CountryChina
- Language:Chinese
-
Abstract:
Ulcerative colitis (UC) is a chronic, nonspecific inflammatory disease that affects the intestines.Drug therapy includes 5-aminosalicylic acid (5-ASA) drugs, glucocorticoids, immunomodulators, and biological agents, which can effectively induce and maintain remission and prevent complications.5-ASA is the first-line drug for inducing and maintaining remission in children with mild to moderate UC.Glucocorticoids are the first-line therapy for moderate to severe UC and the second-line remission inducing therapy for patients with mild to moderate UC who do not respond to 5-ASA.Immunomodulators(purine preparations)are suitable for maintenance remission therapy after steroid dependence, 5-ASA intolerance, frequent recurrence, and acute severe UC response to hormone-induced therapy.Calcineurin inhibitors and the biological agent infliximab can be used as second-line treatment for patients with acute severe UC who do not respond to glucocorticoids therapy.Vedolizumab and ustekinumab can be used as second-line biotherapy after failure of anti-tumor necrosis factor-α, but data are lacking in studies of pediatric UC.The purpose of this article is to review the progress of drug therapy for children with UC, and provide reference for clinical practice.
